Explore By Subject Area   
Return Home
Register Here Menu

Immuno-Oncology 360°

Date: Mar 24, 2025 - Mar 26, 2025

Location: Boston, MA

Day Two: Wednesday, February 28, 2024
Showing Events in 1 Track from 07:45am to 09:20am
Day 2 Morning General Session
7:45AM - 8:05AM
Registration
8:05AM - 8:15AM
IO360° Day Two Welcome
Chair:
James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
Priti Hegde, PhD, SVP and Global Head of Research, Kite Pharma, a Gilead Company
8:15AM - 8:35AM
Analyst Keynote: What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum
Keynote:
Andrew Baum, MD, Head of Global Healthcare; Managing Director, Equity Research, Citi
8:35AM - 9:00AM
Zeitgeist Talk: Immuno-Oncology Lessons from the Past 10 Years that Can Help Advance Cancer Immunotherapies
Speaker:
Jason Luke, MD, FACP, Associate Director for Clinical Research and Director, Immunotherapy and Drug Development Center / Associate Professor of Medicine, UPMC Hillman Cancer Center / University of Pittsburgh
9:00AM - 9:20AM
Fireside Chat: The Personal Impact of an Immunotherapy Trial
VIP Patient Guests:
Kelly Spill-Bonito, Patient, Advocate
Cindy Geoghegan, Patient, Advocate
Showing Events in 1 Track from 09:20am to 09:40am
State of the IO Market, Investments and Deals
9:20AM - 9:40AM
Biotech Markets & IO Outlook
Speaker:
Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley
Showing Events in 1 Track from 09:40am to 10:20am
Morning IO360° Breakfast, Networking, Exhibits & One-On-One Meetings
9:40AM - 10:20AM
Morning IO360° Breakfast, Networking, Exhibits & One-On-One Meetings
Showing Events in 2 Tracks from 10:20am to 10:50am
IO360° Biotech Showcase A (Salon ABC)
Track Chair:
Graig C. Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA
10:20AM - 10:50AM
IO360° Biotech Showcase A
Speakers:
David Burkhart, PhD, COO, Inimmune
Nathanael McCurley, PhD, Vice President, Research and Development, SIRPant Immunotherapeutics
Joanne Hulme, PhD, Chief Scientific Officer, Radiant Biotherapeutics
Matthew Martin, PhD, MBA, CEO, Saros Therapeutics
William Jia, PhD, CSO & Co-founder, Virogin Biotech
Participating Companies to date Include:
IO360° Biotech Showcase B (Northside Ballroom)
Track Chair:
Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist Securities
10:20AM - 10:50AM
IO360° Biotech Showcase B
Speaker:
Tehila Ben Moshe, PhD, CEO, Biond Biologics
Hongtao Lu, PhD, Co-Founder, Chief Scientific Officer, Elpiscience Biopharma
Livija Deban, PhD, CSO, Prokarium
Lars Prestegarden, CEO, Cytovation
Jay Fine, PhD, President, Research & Development, EvolveImmune Therapeutics
Participating Companies to date Include:
Showing Events in 1 Track from 10:50am to 12:30pm
State of the IO Market, Investments and Deals Continued
Track Chair:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
10:50AM - 11:10AM
Fireside Chat: Public Investing in a Difficult IPO Market
Fireside Guest:
Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments
Moderated By:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
11:10AM - 11:50AM
Leveraging the Rise of China Biotech in IO: Pros & Cons
Co-moderated by:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Leon 'Jun' Tang, PhD, Founder / Scientific Advisor, InScienceWeTrust BioAdvisory / Mianus Capital
Panelist:
Jing Li, MD, PhD, MBA, Founder, CEO, VelaVigo
Jie Liu, MBA, Managing Director, STIFEL
Leo MacDonald, MBA, Vice President, BD Transactions – Hematology & I/O, J&J Innovative Medicine
11:50AM - 12:30PM
Investment Trends in IO Panel
Moderated by:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Panelists:
Irina Margine, PhD, Principal, Biotech Private Equity, Wellington Management
Khalil Barrage, Managing Partner, Invus Group
Jeffrey Bockman, PhD, EVP, Oncology and Virology Practices, Lumanity
Emmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, Merck
Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca
Showing Events in 1 Track from 12:30pm to 01:25pm
Lunch
12:30PM - 1:25PM
Lunch & One-on-One Meetings
Showing Events in 2 Tracks from 01:25pm to 03:25pm
Track A: Translational Science, Imaging & Biomarkers (Salon DE)
Track Chair:
David Feltquate, MD, PhD, CMO, Palleon Pharmaceuticals
1:25PM - 1:45PM
Update on Moderna’s Individualized Neoantigen Therapy (INT) with Lower Disease Burden
Speaker:
Robert Meehan, MD, Senior Director, Clinical Development, Moderna
1:45PM - 2:05PM
Microbiome-based Interventions for Improving Patient Outcomes in Oncology
Speaker:
Saman Maleki, PhD, Assistant Professor, Ontario Institute for Cancer Research, University of Western Ontario
2:05PM - 2:25PM
Exploring the Use of ctDNA for Monitoring Treatment Response: Findings from the ctMoniTR Project
Speaker:
Jeff Allen, PhD, CEO & President, Friends of Cancer Research (FOCR)
2:25PM - 2:45PM
Predicting Efficacy and Toxicities Prior to Immune Checkpoint Inhibitor Treatment
Speakers:
Jan Wolber, PhD, Global Product Leader Digital Pharmaceutical Diagnostics, GE Healthcare
Travis Osterman, DO, Assistant Professor, Department of Biomedical Informatics, Assistant Professor, Division of Hematology and Oncology / Director or Cancer Clinical Informatics, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center
2:45PM - 3:05PM
Intracranial Response with Biologics: Lessons and Relevance in IO
Speaker:
David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
3:05PM - 3:25PM
Advancing Prostate Cancer Care through Radioligand Therapy
Speaker:
Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
Track B: IO Cell Therapy (Northside Ballroom)
Track Chair:
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS
1:25PM - 1:35PM
Cell Therapy Welcome: Harnessing Data to Iterate the Next Generation of Cell Therapies
Co-Chairs:
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS
1:35PM - 2:00PM
Keynote: From Bedside Back to Bench: Discoveries from the Clinic that Help Inform Cell Therapy Moving Forward
Speaker:
Kristen Hege, MD, Independent Board Member, Adaptimmune, Mersana & Graphite Bio
2:00PM - 2:20PM
Data Extrapolation to Accelerate Next Gen Cellular Immunotherapies
Speaker:
Mark Stewart, PhD, VP, Science Policy, Friends of Cancer Research (FOCR)
2:20PM - 2:40PM
IO Cell Therapy Data Analytics: What to Measure and How to Measure it?
Speakers:
Christine Brown, PhD, Deputy Director, T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope
2:40PM - 3:25PM
Panel: Key Learnings from Manufacturing to Help Accelerate the Process and Development of Cancer Cell-based Immunotherapies
Moderated by:
Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
Panelist:
Arvind Natarajan, PhD, MBA, SVP, Process and Analytical Development, Iovance Biotherapeutics Inc
Greg Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics
Shishir Gadam, PhD, Chief Technical Officer, Cargo Therapeutics
Jessica Carmen, PhD, Vice President of Business Development, Kincell Bio
Angela Chen, PhD, Chief Business Officer, WuXi Advanced Therapies
Showing Events in 1 Track from 03:25pm to 04:05pm
Afternoon Break
3:25PM - 4:05PM
Afternoon Break and One-on-One Meetings
Showing Events in 4 Tracks from 04:05pm to 05:05pm
Track A: Translational Science, Imaging & Biomarkers A (Salon D)
Track Chair:
Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences
4:05PM - 4:45PM
Panel: Synergizing Radiopharmaceutical Therapy and Immunotherapy for Optimal Cancer Treatment Outcomes
Moderated by:
Ohad Ilovich, PhD, Director, Head of Clinical Imaging, Amgen
Panelists:
Elaine Long, PhD, Scientific Leader, Immuno-Oncology, GE HealthCare
Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
Jack Hoppin, PhD, Founder and CEO, Ratio Therapeutics
Ron Korn, MD, PhD, Founder and Chief Medical Officer, Imaging Endpoints
4:45PM - 5:00PM
Unraveling Immune Therapy Efficacy Through Growth Kinetics Modeling: A Descriptive Analysis of Imaging Kinetic Biomarkers Using RECIST 1.1 Assessments
Speaker:
Antoine Iannessi, MD, Head of Medical Affairs, iCRO Business Unit, Median Technologies
Track B: Translational Science, Imaging & Biomarkers B (Salon E)
Track Chair:
Maria Jure-Kunkel, DVM, PhD, VP, Translational Medicine, Genmab
4:05PM - 4:45PM
Unlocking the Potential of ctDNA for Prognostic Stratification, Tumor Evolution Insights, and Accelerated Drug Development
Moderated by:
Matthew Silver, PhD, Head, Companion Diagnostics, Takeda
Panelist:
John Simmons, PhD, Global VP, Biopharma Partnerships, Natera
Reshma Patel, Director and Global Regulatory Lead, J&J Innovative Medicine
Jeff Allen, PhD, CEO & President, Friends of Cancer Research (FOCR)
4:45PM - 5:00PM
Leveraging Digital Technology for Accelerated Translational Research: Astellas Innovations
Speakers:
Takeshi Saito, PhD, Director, Translational Bioinformatics Lead, Translational Medicine, Astellas Pharma US
Track C: Cell Therapy: Discovery Hypothesis Generating Data (Northside Ballroom)
Track Chair:
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
4:05PM - 4:25PM
Lab Discoveries to Inform Cell Therapy Development
Speaker:
Caleb Lareau, PhD, Principal Investigator & Assistant Professor, Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center
4:25PM - 4:45PM
Building Better Immunotherapies through Genome-scale Discovery of Key Nodes of T cell Function
Speaker:
Mat Legut, PhD, CEO, OverT Bio
4:45PM - 5:05PM
Designing a Logic Gated Product and an AML Trial for CAR NK Cell Therapy: Incorporating Lessons Learned from the Field
Speaker:
Kanya Rajangam, MD, PhD, Head, R&D and CMO, Senti Bio
Track D: Cell Therapy: Data From The Clinic (Salon ABC)
Track Chair:
Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS
4:05PM - 4:20PM
Turbocharging T cells: Learnings from Clinical Studies Leveraging the T-Charge™ Platform
Speaker:
Serena De Vita, MD, PhD, Global Head of Hematology, Translational Clinical Oncology, Novartis Institutes for BioMedical Research (NIBR)
4:20PM - 4:35PM
AI-Powered Identification of Neurotoxicity Predictive Cell Signature in CAR-T Cell Therapy for DLBCL
Speaker:
Diana Stoycheva, PhD, Principal Scientist, Scailyte AG
4:35PM - 4:50PM
Resistance to CART Immunotherapy for Lymphoma and Novel Strategies to Overcome it
Speaker:
Marco Ruella, MD, Assistant Professor of Medicine, Scientific Dir. Lymphoma Program, Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania
4:50PM - 5:05PM
BMS Discoveries from Cell Therapy Correlative Research Initiatives
Speaker:
Allison Kaeding, MD, Senior Director, Early Clinical Development: IO and Cell Therapy, BMS
Showing Events in 1 Track from 05:15pm to 05:55pm
IO360° Cancer Immunotherapy Debate (Salon DE)
5:15PM - 5:55PM
IO360° Annual Debate: Top Next Gen Approaches to Challenges in Cancer Immunotherapy
Moderated by:
William Ho, MBA, President & CEO, IN8Bio
Participants:
Alex Snyder, MD, EVP, Research and Development, Generate Biomedicines
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
Kristen Hege, MD, Independent Board Member, Adaptimmune, Mersana & Graphite Bio
Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine
Naiyer Rizvi, MD, CMO, Synthekine
Showing Events in 1 Track from 06:30pm to 07:30pm
Brooklyn Heights Historical Walk
6:30PM - 7:30PM
Pre-Registration Required: Guided Brooklyn Heights Historical Walk
Showing Events in 1 Track from 07:45am to 09:20am
Day 2 Morning General Session
7:45AM - 8:05AM
Registration
8:05AM - 8:15AM
IO360° Day Two Welcome
Chair:
James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
Priti Hegde, PhD, SVP and Global Head of Research, Kite Pharma, a Gilead Company
8:15AM - 8:35AM
Analyst Keynote: What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum
Keynote:
Andrew Baum, MD, Head of Global Healthcare; Managing Director, Equity Research, Citi
8:35AM - 9:00AM
Zeitgeist Talk: Immuno-Oncology Lessons from the Past 10 Years that Can Help Advance Cancer Immunotherapies
Speaker:
Jason Luke, MD, FACP, Associate Director for Clinical Research and Director, Immunotherapy and Drug Development Center / Associate Professor of Medicine, UPMC Hillman Cancer Center / University of Pittsburgh
9:00AM - 9:20AM
Fireside Chat: The Personal Impact of an Immunotherapy Trial
VIP Patient Guests:
Kelly Spill-Bonito, Patient, Advocate
Cindy Geoghegan, Patient, Advocate
Showing Events in 1 Track from 09:20am to 09:40am
State of the IO Market, Investments and Deals
9:20AM - 9:40AM
Biotech Markets & IO Outlook
Speaker:
Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley
Showing Events in 1 Track from 09:40am to 10:20am
Morning IO360° Breakfast, Networking, Exhibits & One-On-One Meetings
9:40AM - 10:20AM
Morning IO360° Breakfast, Networking, Exhibits & One-On-One Meetings
Showing Events in 2 Tracks from 10:20am to 10:50am
IO360° Biotech Showcase A (Salon ABC)
Track Chair:
Graig C. Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA
10:20AM - 10:50AM
IO360° Biotech Showcase A
Speakers:
David Burkhart, PhD, COO, Inimmune
Nathanael McCurley, PhD, Vice President, Research and Development, SIRPant Immunotherapeutics
Joanne Hulme, PhD, Chief Scientific Officer, Radiant Biotherapeutics
Matthew Martin, PhD, MBA, CEO, Saros Therapeutics
William Jia, PhD, CSO & Co-founder, Virogin Biotech
Participating Companies to date Include:
IO360° Biotech Showcase B (Northside Ballroom)
Track Chair:
Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist Securities
10:20AM - 10:50AM
IO360° Biotech Showcase B
Speaker:
Tehila Ben Moshe, PhD, CEO, Biond Biologics
Hongtao Lu, PhD, Co-Founder, Chief Scientific Officer, Elpiscience Biopharma
Livija Deban, PhD, CSO, Prokarium
Lars Prestegarden, CEO, Cytovation
Jay Fine, PhD, President, Research & Development, EvolveImmune Therapeutics
Participating Companies to date Include:
Showing Events in 1 Track from 10:50am to 12:30pm
State of the IO Market, Investments and Deals Continued
Track Chair:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
10:50AM - 11:10AM
Fireside Chat: Public Investing in a Difficult IPO Market
Fireside Guest:
Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments
Moderated By:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
11:10AM - 11:50AM
Leveraging the Rise of China Biotech in IO: Pros & Cons
Co-moderated by:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Leon 'Jun' Tang, PhD, Founder / Scientific Advisor, InScienceWeTrust BioAdvisory / Mianus Capital
Panelist:
Jing Li, MD, PhD, MBA, Founder, CEO, VelaVigo
Jie Liu, MBA, Managing Director, STIFEL
Leo MacDonald, MBA, Vice President, BD Transactions – Hematology & I/O, J&J Innovative Medicine
11:50AM - 12:30PM
Investment Trends in IO Panel
Moderated by:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Panelists:
Irina Margine, PhD, Principal, Biotech Private Equity, Wellington Management
Khalil Barrage, Managing Partner, Invus Group
Jeffrey Bockman, PhD, EVP, Oncology and Virology Practices, Lumanity
Emmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, Merck
Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca
Showing Events in 1 Track from 12:30pm to 01:25pm
Lunch
12:30PM - 1:25PM
Lunch & One-on-One Meetings
Showing Events in 2 Tracks from 01:25pm to 03:25pm
Track A: Translational Science, Imaging & Biomarkers (Salon DE)
Track Chair:
David Feltquate, MD, PhD, CMO, Palleon Pharmaceuticals
1:25PM - 1:45PM
Update on Moderna’s Individualized Neoantigen Therapy (INT) with Lower Disease Burden
Speaker:
Robert Meehan, MD, Senior Director, Clinical Development, Moderna
1:45PM - 2:05PM
Microbiome-based Interventions for Improving Patient Outcomes in Oncology
Speaker:
Saman Maleki, PhD, Assistant Professor, Ontario Institute for Cancer Research, University of Western Ontario
2:05PM - 2:25PM
Exploring the Use of ctDNA for Monitoring Treatment Response: Findings from the ctMoniTR Project
Speaker:
Jeff Allen, PhD, CEO & President, Friends of Cancer Research (FOCR)
2:25PM - 2:45PM
Predicting Efficacy and Toxicities Prior to Immune Checkpoint Inhibitor Treatment
Speakers:
Jan Wolber, PhD, Global Product Leader Digital Pharmaceutical Diagnostics, GE Healthcare
Travis Osterman, DO, Assistant Professor, Department of Biomedical Informatics, Assistant Professor, Division of Hematology and Oncology / Director or Cancer Clinical Informatics, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center
2:45PM - 3:05PM
Intracranial Response with Biologics: Lessons and Relevance in IO
Speaker:
David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
3:05PM - 3:25PM
Advancing Prostate Cancer Care through Radioligand Therapy
Speaker:
Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
Track B: IO Cell Therapy (Northside Ballroom)
Track Chair:
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS
1:25PM - 1:35PM
Cell Therapy Welcome: Harnessing Data to Iterate the Next Generation of Cell Therapies
Co-Chairs:
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS
1:35PM - 2:00PM
Keynote: From Bedside Back to Bench: Discoveries from the Clinic that Help Inform Cell Therapy Moving Forward
Speaker:
Kristen Hege, MD, Independent Board Member, Adaptimmune, Mersana & Graphite Bio
2:00PM - 2:20PM
Data Extrapolation to Accelerate Next Gen Cellular Immunotherapies
Speaker:
Mark Stewart, PhD, VP, Science Policy, Friends of Cancer Research (FOCR)
2:20PM - 2:40PM
IO Cell Therapy Data Analytics: What to Measure and How to Measure it?
Speakers:
Christine Brown, PhD, Deputy Director, T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope
2:40PM - 3:25PM
Panel: Key Learnings from Manufacturing to Help Accelerate the Process and Development of Cancer Cell-based Immunotherapies
Moderated by:
Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
Panelist:
Arvind Natarajan, PhD, MBA, SVP, Process and Analytical Development, Iovance Biotherapeutics Inc
Greg Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics
Shishir Gadam, PhD, Chief Technical Officer, Cargo Therapeutics
Jessica Carmen, PhD, Vice President of Business Development, Kincell Bio
Angela Chen, PhD, Chief Business Officer, WuXi Advanced Therapies
Showing Events in 1 Track from 03:25pm to 04:05pm
Afternoon Break
3:25PM - 4:05PM
Afternoon Break and One-on-One Meetings
Showing Events in 4 Tracks from 04:05pm to 05:05pm
Track A: Translational Science, Imaging & Biomarkers A (Salon D)
Track Chair:
Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences
4:05PM - 4:45PM
Panel: Synergizing Radiopharmaceutical Therapy and Immunotherapy for Optimal Cancer Treatment Outcomes
Moderated by:
Ohad Ilovich, PhD, Director, Head of Clinical Imaging, Amgen
Panelists:
Elaine Long, PhD, Scientific Leader, Immuno-Oncology, GE HealthCare
Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
Jack Hoppin, PhD, Founder and CEO, Ratio Therapeutics
Ron Korn, MD, PhD, Founder and Chief Medical Officer, Imaging Endpoints
4:45PM - 5:00PM
Unraveling Immune Therapy Efficacy Through Growth Kinetics Modeling: A Descriptive Analysis of Imaging Kinetic Biomarkers Using RECIST 1.1 Assessments
Speaker:
Antoine Iannessi, MD, Head of Medical Affairs, iCRO Business Unit, Median Technologies
Track B: Translational Science, Imaging & Biomarkers B (Salon E)
Track Chair:
Maria Jure-Kunkel, DVM, PhD, VP, Translational Medicine, Genmab
4:05PM - 4:45PM
Unlocking the Potential of ctDNA for Prognostic Stratification, Tumor Evolution Insights, and Accelerated Drug Development
Moderated by:
Matthew Silver, PhD, Head, Companion Diagnostics, Takeda
Panelist:
John Simmons, PhD, Global VP, Biopharma Partnerships, Natera
Reshma Patel, Director and Global Regulatory Lead, J&J Innovative Medicine
Jeff Allen, PhD, CEO & President, Friends of Cancer Research (FOCR)
4:45PM - 5:00PM
Leveraging Digital Technology for Accelerated Translational Research: Astellas Innovations
Speakers:
Takeshi Saito, PhD, Director, Translational Bioinformatics Lead, Translational Medicine, Astellas Pharma US
Track C: Cell Therapy: Discovery Hypothesis Generating Data (Northside Ballroom)
Track Chair:
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
4:05PM - 4:25PM
Lab Discoveries to Inform Cell Therapy Development
Speaker:
Caleb Lareau, PhD, Principal Investigator & Assistant Professor, Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center
4:25PM - 4:45PM
Building Better Immunotherapies through Genome-scale Discovery of Key Nodes of T cell Function
Speaker:
Mat Legut, PhD, CEO, OverT Bio
4:45PM - 5:05PM
Designing a Logic Gated Product and an AML Trial for CAR NK Cell Therapy: Incorporating Lessons Learned from the Field
Speaker:
Kanya Rajangam, MD, PhD, Head, R&D and CMO, Senti Bio
Track D: Cell Therapy: Data From The Clinic (Salon ABC)
Track Chair:
Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS
4:05PM - 4:20PM
Turbocharging T cells: Learnings from Clinical Studies Leveraging the T-Charge™ Platform
Speaker:
Serena De Vita, MD, PhD, Global Head of Hematology, Translational Clinical Oncology, Novartis Institutes for BioMedical Research (NIBR)
4:20PM - 4:35PM
AI-Powered Identification of Neurotoxicity Predictive Cell Signature in CAR-T Cell Therapy for DLBCL
Speaker:
Diana Stoycheva, PhD, Principal Scientist, Scailyte AG
4:35PM - 4:50PM
Resistance to CART Immunotherapy for Lymphoma and Novel Strategies to Overcome it
Speaker:
Marco Ruella, MD, Assistant Professor of Medicine, Scientific Dir. Lymphoma Program, Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania
4:50PM - 5:05PM
BMS Discoveries from Cell Therapy Correlative Research Initiatives
Speaker:
Allison Kaeding, MD, Senior Director, Early Clinical Development: IO and Cell Therapy, BMS
Showing Events in 1 Track from 05:15pm to 05:55pm
IO360° Cancer Immunotherapy Debate (Salon DE)
5:15PM - 5:55PM
IO360° Annual Debate: Top Next Gen Approaches to Challenges in Cancer Immunotherapy
Moderated by:
William Ho, MBA, President & CEO, IN8Bio
Participants:
Alex Snyder, MD, EVP, Research and Development, Generate Biomedicines
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Michael Kalos, PhD, Managing Director, Next Pillar Consulting
Kristen Hege, MD, Independent Board Member, Adaptimmune, Mersana & Graphite Bio
Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine
Naiyer Rizvi, MD, CMO, Synthekine
Showing Events in 1 Track from 06:30pm to 07:30pm
Brooklyn Heights Historical Walk
6:30PM - 7:30PM
Pre-Registration Required: Guided Brooklyn Heights Historical Walk

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.